20/20 Biolabs Inc. (AIDX)
20/20 Biolabs Inc. (AIDX) Stock Price, Analysis & Data
| Bid | 0.61 |
| Market Cap | 5.62M |
| Revenue (ttm) | 1.84M |
| Net Income (ttm) | -5.09M |
| Beta | n/a |
| EPS (ttm) | -0.49 |
| PE Ratio (ttm) | n/a |
| Forward PE | n/a |
| P/B (ttm) | 1.88 |
| P/S (ttm) | 3.05 |
| Earnings Date | n/a |
| Ask | 1 |
| Volume | 53,024 |
| Avg. Volume (20D) | 796,940 |
| Open | 0.44 |
| Previous Close | 0.44 |
| Day's Range | 0.44 - 0.50 |
| 52-Week Range | 0.40 - 50.00 |
| Analyst | n/a |
| Price Target | 5 (986.96%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About AIDX
20/20 Biolabs, Inc. develops and commercializes AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. It provides OneTest for Cancer, a multi-cancer early detection, or MCED and OneTest for Longevity, which measures inflammatory biomarkers. It also operates the Clinical Lab Innovation Axcelerator (CLIAx), a CLIA laboratory for overseas diagnostics start-ups. The company was formerly known...
Financial Performance
In 2025, 20/20 Biolabs's revenue was 2.05M, an increase of 16.71% compared to the previous year's 1.75M. Earnings were -3.74M, a decrease of -32.65%.
Financial StatementsAnalyst Forecast
According to 1 analyst ratings, the average rating for AIDX stock is "null". The 12-month stock price forecast is 5, which is upside of 986.96% from the latest price.
Stock Forecasts